CNR1 and attention deficit-hyperactivity disorder: Interventional trials targeting NAE elevation (e.g., via PEA supplementation) could validate therapeutic efficacy, while investigating gene–environment interactions (e.g., CNR1 polymorphisms) may elucidate why some ADHD subtypes exhibit divergent endocannabinoid profiles.